Skip to main content

Advertisement

SpringerLink
Log in

Guillain-barré syndrome

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

  • •Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy. Two thirds of GBS patients are unable to walk at their most severe state of disease. Respiratory insufficiency and autonomic failure are probably the main causes of death. Optimal general care, physiotherapy and the availability of intensive care facilities at short distance are of great importance.

  • •Randomized controlled trials show that intravenous immune globulin (IVIg) and plasma exchange (PE) are equally effective in reducing the time to functional recovery. The combination of PE followed by IVIg, is not significantly better than IVIg or PE alone. Corticosteroids alone are not effective in GBS.

  • •Approximately 10% of GBS patients deteriorate after initial improvement or stabilization following IVIg or PE treatment, and often require repeated treatment. These ‘treatment related clinical fluctuations’ are more frequently seen in relatively young patients with severe motor and sensory involvement associated with a preceding and possibly ongoing cytomegalovirus infection.

  • •Predominantly motor GBS is frequently preceded by a Campylobacter jejeuni infection. Diarrhea prior to GBS is associated with a worse predicted outcome. Further confirmation is needed to determine whether this is especially the case in those patients treated with PE.

  • •GBS patients who are unable to walk without assistance, and who are still within their first 2 weeks of the disease, need to be treated. One PE study showed that patients who are only mildly disabled showed positive progress from two plasma exchange sessions.

  • •Presently, due to its wide availability, ease of administration, and favorable side-effect profile, IVIg is considered to be the first-line treatment for patients with GBS. Current investigations are trying to determine if IVIg used in combination with methylprednisolone is even more effective in treating GBS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Koningsveld R, Van Doorn PA, Schmitz PI, et al.: Mild forms of Guillain-Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000, 54:620–625.

    PubMed  Google Scholar 

  2. Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barré syndrome [review]. Ann Neurol 1990, 27(suppl):S21-S24.

    Article  PubMed  Google Scholar 

  3. Ad Hoc Committee WHO-AIREN: Acute onset flaccid paralysis. Geneva: World Health Organization; 1993.

    Google Scholar 

  4. Hahn AF: Guillain-Barré syndrome. Lancet 1998, 352:635–641. A very useful review of GBS.

    Article  PubMed  CAS  Google Scholar 

  5. Cornblath DR, Asbury AK, Albers JW, et al.: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991, 41:617–618.

    Google Scholar 

  6. Hughes RA, Sanders E, Hall S, et al.: Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992, 49:612–616.

    PubMed  CAS  Google Scholar 

  7. Rees JH, Soudain SE, Gregson NA, et al.: Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995, 333:1374–1379.

    Article  PubMed  CAS  Google Scholar 

  8. Jacobs BC, Rothbart PH, Van der Meché FG: The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998, 51:1110–1115.

    PubMed  CAS  Google Scholar 

  9. Hartung HP, Van der Meché FGA, Pollard JD: Guillain-Barré syndrome, CIDP and other chronic immune mediated neuropathies. Curr Opin Neurol 1998, 11:497–513. This is a comprehensive review of immune-mediated polyneuropathies. It discusses immunopathogenesis and treatment.

    Article  PubMed  CAS  Google Scholar 

  10. Ho TW, Mishu B, Li CY, et al.: Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597–605.

    Article  PubMed  Google Scholar 

  11. Hao Q, Saida T, Kuroki S, et al.: Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 1998, 81:116–126.

    Article  PubMed  CAS  Google Scholar 

  12. Feasby TE, Hughes RA: Campylobacter jejuni, antiganglioside antibodies, and Guillain-Barré syndrome [editorial]. Neurology 1998, 51:340–342.

    PubMed  CAS  Google Scholar 

  13. Ang CW, Jacobs BC, Brandenburg AH, et al.: Crossreactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barre syndrome. Neurology 2000, 54:1453–1458.

    PubMed  CAS  Google Scholar 

  14. Goodyear CS, O’Hanlon GM, Plomp JJ, et al.: Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999, 104:697–708.

    Article  PubMed  CAS  Google Scholar 

  15. The Guillain-Barré Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985, 35:1096–1104.

    Google Scholar 

  16. Anonymous: Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1992, 32:94–97.

    Google Scholar 

  17. Van der Meché FG, Schmitz PIM, Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992, 326:1123–1129. This is the first trial showing that IVIg is an effective treatment in GBS.

    Article  PubMed  Google Scholar 

  18. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/ Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997, 349:225–230. This is the largest treatment trial in patients with GBS. It shows that PE and IVIg are equally effective, and that the combination is not significantly better.

  19. Anonymous: Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré syndrome steroid trial group. Lancet 1993, 341:586–590.

    Google Scholar 

  20. Hughes RA, Van der Meché FG: Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev 2000, 2:CD0014466. This systematic Cochrane review showed that treatment of GBS patients with corticosteroids alone is not effective.

    Google Scholar 

  21. Anonymous: Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol 1994, 35:749–752.

    Google Scholar 

  22. Anonymous: Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997, 41:298–306. This is the first trial that evaluated the effect of PE in patients who are only mildly disabled. Additionally it studied the response to a different number of PE sessions.

    Google Scholar 

  23. Van der Meché, Van Doorn PA: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995, 37:S14-S31.

    Article  PubMed  Google Scholar 

  24. Visser LH, Van der Meché FG, Meulstee J, et al.: Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry 1998, 64:242–244.

    PubMed  CAS  Google Scholar 

  25. Visser LH, Schmitz PI, Meulstee J, et al.: Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 1999, 53:5980–6044. This study describes prognostic factors related to outcome at 8 weeks and 6 months after onset of GBS. A new prognostic factor is the presence of a cytomegalovirus infection.

    Google Scholar 

  26. Guillain-Barré Syndrome Steroid Trial Group: Doubleblind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993, 341:586–590.

    Google Scholar 

  27. Dalakas MC: Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999, 22:1479–1977. This review summarizes the current status of IVIg in the treatment of autoimmune neuromuscular disorders. It gives guidelines for treatment and discusses mechanisms of action of IVIg.

    Article  PubMed  CAS  Google Scholar 

  28. Sharief MK, Ingram DA, Swash M, et al.: I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999, 52:1833–1838.

    PubMed  CAS  Google Scholar 

  29. Thornton CA, Griggs RC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994, 35:260–268.

    Article  PubMed  CAS  Google Scholar 

  30. Nagpal S, Benstead T, Shumak K, et al.: Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apheresis 1999, 14:107–13.

    Article  PubMed  CAS  Google Scholar 

  31. Chen WH, Yeh JH, Chiu HC: Experience of double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. J Clin Apheresis 1999, 14:126–129.

    Article  PubMed  CAS  Google Scholar 

  32. Tagawa Y, Yuki N, Hirata K: Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain-Barré syndrome: is it equivalent to plasma exchange? Ther Apher 1997, 1:336–339.

    PubMed  CAS  Google Scholar 

  33. Wollinsky KH, Hulser PJ, Brinkmeyer H, et al.: Filtration of cerebrospinal fluid in acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). Ann Med Interne (Paris) 1994, 145:451–488.

    CAS  Google Scholar 

  34. Anonymous: Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997, 41:298–306.

    Google Scholar 

  35. Bernsen RA, De Jager AE, Schmitz PI, et al.: Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999, 53:409–410.

    PubMed  CAS  Google Scholar 

  36. Merkies IS, Schmitz PI, Samijn JP, et al.: Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999, 53:1648–1654. This carefully executed study evaluated the use of the fatigue severity scale in patients with immune-mediated polyneuropathies. It shows that fatigue and impaired endurance is a major symptom in patients with GBS. It may persist for years after apparent recovery.

    PubMed  CAS  Google Scholar 

  37. Tripathi M, Kaushik S: Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 2000, 28:655–658.

    Article  PubMed  CAS  Google Scholar 

  38. Creange A, Lerat H, Meyrignac C, et al.: Treatment of Guillain-Barré syndrome with interferon-beta [letter]. Lancet 1998, 352:368–369.

    Article  PubMed  CAS  Google Scholar 

  39. Sawaya RA: Interferon beta for Guillain-Barré syndrome [letter]. Lancet 1998, 352:1550–1551.

    Article  PubMed  CAS  Google Scholar 

  40. Nicoletti F, Nicoletti A, Giuffrida S, et al.: Sodium fusidate in Guillain-Barré syndrome: a case report. J Neurol Neurosurg Psychiatry 1998, 65:266–268.

    Article  PubMed  CAS  Google Scholar 

  41. Hood KA, Zarembski DG: Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997, 54:285–294.

    PubMed  CAS  Google Scholar 

  42. Graf WD, Katz JS, Eder DN, et al.: Outcome in severe pediatric Guillain-Barre syndrome after immunotherapy or supportive care. Neurology 1999, 52:1494–1497.

    PubMed  CAS  Google Scholar 

  43. Goodhew PM, Johnston HM: Immune globulin therapy in children with Guillain-Barré syndrome. Muscle Nerve 1996, 19:1490–1492.

    Article  PubMed  CAS  Google Scholar 

  44. Gursus N, Uysal S, Cetinkaya F, et al.: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995, 27:241–243.

    Google Scholar 

  45. Kanra G, Ozon A, Vajsar J, et al.: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Europ J Paediatr Neurol 1997, 1:7–12.

    Article  CAS  Google Scholar 

  46. Visser LH, Van der Meché FGA, Van Doorn PA, et al.: Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995, 118:841–847.

    Article  PubMed  Google Scholar 

  47. Visser LH, Van der Meché FGA, Meulstee J, et al.: Cytomegalovirus infection and Guillain-Barré syndrome; the clinical, electrophysiologic and prognostic features. Neurology 1996, 47:668–673.

    PubMed  CAS  Google Scholar 

  48. Yuki N, Ang CW, Koga M, et al.: Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314–321.

    Article  PubMed  CAS  Google Scholar 

  49. Ang CW, Yuki N, Jacobs BC, et al.: Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology 1999, 53:2122–2127.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Rotterdam, Dr. Molewaterplein 40, 3015, GD Rotterdam, The Netherlands

    Franz G. A. van der Meché MD & Pieter A. van Doorn MD

Authors
  1. Franz G. A. van der Meché MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter A. van Doorn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Meché, F.G.A., van Doorn, P.A. Guillain-barré syndrome. Curr Treat Options Neurol 2, 507–516 (2000). https://doi.org/10.1007/s11940-000-0029-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-000-0029-7

Keywords

Search

Navigation